China Medical Technologies, which produces in-vitro diagnostic products, will pay $345 million to purchase the rights for a human papillomavirus (HPV) test from Molecular Diagnostics Technologies Limited. China Medical will buy the HPV-DNA Biosensor Chip and Surface Plasmon Resonance-based Analysis System (the SPR System), which can detect the virus that causes cervical cancer and sexually transmitted disorders. China Medical has profited by acquiring other in vitro technologies, most recently the FISH (Fluorescent in situ Hybridization) system. The SPR System will become part of the company’s FISH offerings. More details...

Stock Symbol: (NSDQ: CMED)